EA038285B9 - Human-derived anti-dipeptide repeat (dpr) antibody - Google Patents

Human-derived anti-dipeptide repeat (dpr) antibody

Info

Publication number
EA038285B9
EA038285B9 EA201790433A EA201790433A EA038285B9 EA 038285 B9 EA038285 B9 EA 038285B9 EA 201790433 A EA201790433 A EA 201790433A EA 201790433 A EA201790433 A EA 201790433A EA 038285 B9 EA038285 B9 EA 038285B9
Authority
EA
Eurasian Patent Office
Prior art keywords
dpr
antibodies
antigen binding
binding fragments
c9orf72
Prior art date
Application number
EA201790433A
Other languages
Russian (ru)
Other versions
EA038285B1 (en
EA201790433A1 (en
Inventor
Фабио Монтрасио
Ян Гримм
Original Assignee
Нейриммьюн Холдинг Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нейриммьюн Холдинг Аг filed Critical Нейриммьюн Холдинг Аг
Priority claimed from PCT/EP2015/072516 external-priority patent/WO2016050822A2/en
Publication of EA201790433A1 publication Critical patent/EA201790433A1/en
Publication of EA038285B1 publication Critical patent/EA038285B1/en
Publication of EA038285B9 publication Critical patent/EA038285B9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provides novel human antibodies and antigen binding fragments of said antibodies that bind a protein comprising a dipeptide repeat (DPR-protein) poly-glycine-alanine (GA)15 translated from the chromosome 9 open reading frame 72 (C9orf72) gene, and polynucleotides, expression vectors and host cells for the production of antibodies and antigen binding fragments according to the invention. Furthermore, provided are pharmaceutical compositions comprising antibodies or antigen binding fragments according to the invention for immunotherapy, prevention or diagnostics of diseases or disorders associated with DPR-proteins and/or C9orf72 aggregates, and related methods. The invention also encompasses methods of preparing antibodies and antigen binding fragments according to the invention and quantitative methods of in vivo detection of a protein comprising a dipeptide repeat (DPR) poly-glycine-alanine (GA) in a subject, of such C9orf72.
EA201790433A 2015-08-07 2015-09-30 Human-derived anti-dipeptide repeat (dpr) antibody EA038285B9 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15180310 2015-08-07
PCT/EP2015/072516 WO2016050822A2 (en) 2014-09-30 2015-09-30 Human-derived anti-dipeptide repeats (dprs) antibody

Publications (3)

Publication Number Publication Date
EA201790433A1 EA201790433A1 (en) 2017-09-29
EA038285B1 EA038285B1 (en) 2021-08-04
EA038285B9 true EA038285B9 (en) 2022-03-10

Family

ID=53783654

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201790433A EA038285B9 (en) 2015-08-07 2015-09-30 Human-derived anti-dipeptide repeat (dpr) antibody
EA202092790A EA202092790A1 (en) 2015-08-07 2015-09-30 HUMAN-ORIENTED ANTIBODY TO DIPEPTIDE REPEAT (DPR)

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202092790A EA202092790A1 (en) 2015-08-07 2015-09-30 HUMAN-ORIENTED ANTIBODY TO DIPEPTIDE REPEAT (DPR)

Country Status (1)

Country Link
EA (2) EA038285B9 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014114303A1 (en) * 2013-01-22 2014-07-31 Deutsches Zentrum Für Neurodegenerative Erkrankungen Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
EP2948471A4 (en) * 2013-01-24 2016-08-10 Mayo Foundation Methods and materials for detecting c9orf72 hexanucleotide repeat expansion positive frontotemporal lobar degeneration or c9orf72 hexanucleotide repeat expansion positive amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
EA038285B1 (en) 2021-08-04
EA201790433A1 (en) 2017-09-29
EA202092790A1 (en) 2021-07-30

Similar Documents

Publication Publication Date Title
MX2021011696A (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123.
MX2022015821A (en) Novel t cell receptors and immune therapy using the same.
MX2019006727A (en) Novel t cell receptors and immune therapy using the same.
MX2019006724A (en) Novel t cell receptors and immune therapy using the same.
JO3711B1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
PH12017500489A1 (en) Human-derived anti-dipeptide repeats (dprs) antibody
MX2011012039A (en) Blocking anti-dkk-1 antibodies and their uses.
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
MX2022003706A (en) Human-derived anti-huntingtin (htt) antibodies and uses thereof.
MX2020011312A (en) Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody.
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
MX2021010281A (en) Antigen binding proteins that bind bcma.
PH12017500332A1 (en) Antigen binding proteins that bind cxcr3
CR20190513A (en) Anti-jagged1 antigen binding proteins
EP3974443A3 (en) Peptides derived from melanoma-associated antigen b2 (mageb2)
EA038285B9 (en) Human-derived anti-dipeptide repeat (dpr) antibody
WO2017089781A3 (en) Peptides derived from abnormal spindle-like microcephaly-associated protein (aspm) and complexes comprising such peptides bound to mhc molecules
WO2016040767A3 (en) Chrdl-1 epitopes and antibodies
PH12019501263A1 (en) Novel t cell receptors and immune therapy using the same

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent